Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC).

Saved in:
Bibliographic Details
Title: Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC).
Authors: Mildner FO; Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, 6020, Innsbruck, Austria., Sykora MM; Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, 6020, Innsbruck, Austria; Tyrolean Cancer Research Institute, 6020 Innsbruck, Austria; Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria., Hackl H; Institute of Bioinformatics, Biocenter, Medical University Innsbruck, 6020 Innsbruck, Austria., Amann A; Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, 6020, Innsbruck, Austria., Zelger B; Department of Pathology, Neuropathology, and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Sprung S; Department of Pathology, Neuropathology, and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Buch ML; Department of Visceral, Transplant and Thoracic Surgery, Medical University Innsbruck, 6020 Innsbruck, Austria., Nocera F; Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, 6020, Innsbruck, Austria., Moser P; INNPATH, Institute of Pathology, Tirol Kliniken Innsbruck, 6020 Innsbruck, Austria., Maier H; Department of Visceral, Transplant and Thoracic Surgery, Medical University Innsbruck, 6020 Innsbruck, Austria., Augustin F; Department of Visceral, Transplant and Thoracic Surgery, Medical University Innsbruck, 6020 Innsbruck, Austria., Manzl C; Department of Pathology, Neuropathology, and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria., Kocher F; Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, 6020, Innsbruck, Austria., Pircher A; Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, 6020, Innsbruck, Austria., Lindenmann J; Division of Thoracic and Hyperbaric Surgery, Department of Surgery, Medical University of Graz, 8010 Graz, Austria., Mykoliuk I; Division of Thoracic and Hyperbaric Surgery, Department of Surgery, Medical University of Graz, 8010 Graz, Austria., Raftopoulou S; Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, 8010 Graz, Austria., Kargl J; Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, 8010 Graz, Austria., Wolf D; Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, 6020, Innsbruck, Austria., Sopper S; Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, 6020, Innsbruck, Austria; Tyrolean Cancer Research Institute, 6020 Innsbruck, Austria., Gamerith G; Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, 6020, Innsbruck, Austria. Electronic address: gabi_gamerith@yahoo.de.
Source: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Oct; Vol. 196, pp. 107955. Date of Electronic Publication: 2024 Sep 16.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-8332
DOI:10.1016/j.lungcan.2024.107955